Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial



Status:Recruiting
Conditions:Cervical Cancer, Cardiology, Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:3/27/2019
Start Date:March 9, 2017
End Date:July 2020
Contact:Janet T Holbrook, PhD, MPH
Email:jholbro1@jhu.edu
Phone:443-287-5791

Use our guide to learn which trials are right for you!

The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will
compare the relative efficacy and safety of intravitreal methotrexate, intravitreal
ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular
edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a
parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6
month clinic visit. The primary outcome is percent change in central subfield thickness from
the baseline OCT measurement to the 12 week visit.

Macular edema (ME) is the most common structural complication and cause of visual impairment
and legal blindness in uveitis patients. Traditional approaches to the treatment of uveitic
ME have included the use of regional corticosteroid therapy, delivered periocularly,
including posterior sub-Tenon's and orbital floor injections, or via the intravitreal route.
While corticosteroid injections may reduce ME and improve vision, the effect is often
variable with a limited duration. Persistent macular edema is a common occurrence and often
requires repeated intravitreal injections of corticosteroids, which expose eyes to a
significant risk of increased intraocular pressure ocular and cataract development. The often
refractory nature of uveitic ME and its impact on visual function underscores the need to
identify effective alternative medical therapeutic options. Recent pilot studies have shown
intravitreal methotrexate (MTX) and intravitreal ranibizumab (Lucentis®, Genentech Inc., San
Francisco, CA) to be promising treatments for uveitic ME, and intravitreal dexamethasone
implant (Ozurdex®, Allergan, Irvine, CA) has recently been approved by the U.S. FDA for
uveitic ME in patients with non-infectious uveitis. In addition to being effective,
intravitreal MTX and ranibizumab potentially may have less ocular side effects than
corticosteroids, particularly less IOP elevation. However, the relative efficacy of these
treatments is unknown. The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory
Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal
methotrexate, ranibizumab, and dexamethasone implant. MERIT is a parallel design (1:1:1),
randomized comparative effectiveness trial with an anniversary close-out at the 6 month
clinic visit. The primary outcome is percent change in central subfield thickness from the
baseline OCT measurement to the 12 week visit.

Inclusion criteria:

Patient level inclusion criterion

1. 18 years of age or older;

Eye level inclusion criteria - at least one eye must meet all of the following
conditions

2. Inactive or minimally active non-infectious anterior, intermediate, posterior or
panuveitis, as defined by SUN132 criteria as ≤ 0.5+ anterior chamber cells, ≤ 0.5+
vitreous haze grade and no active retinal/choroidal lesions for a minimum of 4 weeks;

3. Macular edema (ME) defined as the presence of macular thickness greater than the
normal range for the OCT machine being used (see cut points below), regardless of the
presence of cysts, following an intravitreal corticosteroid injection (≥ 4 weeks
following intravitreal triamcinolone injection or ≥ 12 weeks following intravitreal
dexamethasone implant injection);

Greater than 300 μm for Zeiss Cirrus Greater than 320 μm for Heidelberg Spectralis
Greater than 300 μm for Topcon 3DOCT

4. Baseline fluorescein angiogram that, as assessed by the study ophthalmologist, is
gradable for degree of leakage in the central subfield;

5. Best corrected visual acuity (BCVA) 5/200 or better;

6. Baseline intraocular pressure > 5 mm Hg and ≤ 21 mm Hg (current use of ≤3 intraocular
pressure-lowering medications and/or prior glaucoma surgery are acceptable (Note:
combination medications, e.g., Combigan, are counted as two IOP-lowering medications);

7. Media clarity and pupillary dilation sufficient to allow OCT testing and assessment of
the fundus.

Exclusion criteria:

Patient level exclusion criteria

1. History of infectious uveitis in either eye;

2. History of infectious scleritis of any type in either eye (Note: History of
noninfectious scleritis that has been active in past 12 months is an eye-level
exclusion -see #13 below);

3. History of keratitis (with the exception of keratitis due to dry eye) in either eye;

4. History of central serous retinopathy in either eye;

5. Active infectious conjunctivitis in either eye;

6. Oral prednisone dose > 10 mg per day (or of an alternative corticosteroid at a dose
higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose ≤ 10
mg per day at baseline that has not been stable for at least 4 weeks (note: if patient
is off of oral prednisone at baseline (M01 study visit) dose stability requirement for
past 4 weeks does not apply);

7. Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks
(note: use of systemic methotrexate is acceptable as long as regimen has been stable
for at least 4 weeks);

8. Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;

9. Known allergy or hypersensitivity to any component of the study drugs;

10. For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy
test; unwilling to practice an adequate birth control method (abstinence, combination
barrier and spermicide, or hormonal) for duration of trial;

Eye level exclusion criteria - at least one eye that meets all inclusion criteria
cannot have any of the following conditions

11. History of infectious endophthalmitis;

12. History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of ≥ 0.9
or any notching of optic nerve to the rim);

13. History of active noninfectious scleritis in past 12 months (Note: History of
noninfectious scleritis is acceptable if the last episode of active scleritis resolved
at least 12 months prior to enrollment);

14. Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of
study ophthalmologist may be significant enough to limit improvement of ME (i.e.,
causing substantial wrinkling of the retinal surface);

15. Torn or ruptured posterior lens capsule

16. Presence of silicone oil;

17. Ozurdex administered in past 12 weeks;

18. Anti-VEGF agent, intravitreal methotrexate, or intravitreal/periocular corticosteroid
administered in past 4 weeks;

19. Fluocinolone acetonide implant (Retisert) placed in past 3 years.
We found this trial at
20
sites
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Anjum Koreishi, MD
Phone: 312-695-0252
?
mi
from
Chicago, IL
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Steven Yeh, MD
Phone: 404-778-2421
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Jennifer Thorne, MD
Phone: 443-287-4393
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
Principal Investigator: James Folk, MD
Phone: 319-467-5184
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Ann Arbor, Michigan 48105
Principal Investigator: Susan G Elner, MD
Phone: 734-936-0138
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
243 Charles St
Boston, Massachusetts 02114
(617) 523-7900
Principal Investigator: George Papaliodis
Phone: 617-573-5558
Massachusetts Eye & Ear Infirmary Whether you see our physicians at Mass. Eye and Ear's...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Lana M Rifkin, MD
Phone: 617-314-2703
?
mi
from
Boston, MA
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Pauline T Merrill, MD
Phone: 312-563-4031
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Durham, North Carolina 27710
Principal Investigator: Glenn J Jaffe, MD
?
mi
from
Durham, NC
Click here to add this to my saved trials
East Melbourne, Victoria
Principal Investigator: Lyndell Lim
Phone: +61 3 9929 8087
?
mi
from
East Melbourne,
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Rosa Y Kim, MD
Phone: 713-524-3434
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California
Principal Investigator: Gary Holland, MD
Phone: 310-794-5604
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
500 S Preston St
Louisville, Kentucky
(502) 852-5555
Principal Investigator: Harpal S Sandhu, MD FRCSC
Phone: 502-852-5251
University of Louisville The University of Louisville is a state supported research university located in...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Janet Davis, MD
Phone: 305-326-6348
?
mi
from
Miami, FL
Click here to add this to my saved trials
Nashville, Tennessee 37212
Principal Investigator: Sapna Gangaputra, MD
Phone: 615-936-1639
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Nirali Bhatt, MD
Phone: 215-662-8094
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19107
Principal Investigator: James P Dunn, MD
Phone: 215-928-3092
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Principal Investigator: Andrew W Eller, MD
Phone: 412-383-9028
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Albert Vitale, MD
Phone: 801-581-6265
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Nisha Acharya, MD
Phone: 415-476-6687
?
mi
from
San Francisco, CA
Click here to add this to my saved trials